Brooks Laboratories Limited (NSE:BROOKS)

Market Cap	3.98B
Revenue (ttm)	901.36M
Net Income (ttm)	20.31M
Shares Out	29.46M
EPS (ttm)	0.73
PE Ratio	184.64
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,140
Average Volume	45,629
Open	135.01
Previous Close	135.16
Day's Range	132.99 - 139.19
52-Week Range	95.55 - 198.86
Beta	0.69
RSI	33.61
Earnings Date	Aug 12, 2025

About Brooks Laboratories

Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 323
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BROOKS

Financial Performance

In 2024, Brooks Laboratories's revenue was 825.57 million, an increase of 3.86% compared to the previous year's 794.86 million. Losses were -99.67 million, -49.13% less than in 2023.